Development of gene therapy for inner ear disease: Using bilateral vestibular hypofunction as a vehicle for translational research.
Despite the significant impact of hearing and balance disorders on the general population there are currently no dedicated pharmaceuticals that target the inner ear. Advances in molecular biology and neuroscience have improved our understanding of the inner ear allowing the development of a range of molecular targets that have the potential to treat both hearing and balance disorders. One of the principal advantages of the inner ear is that it is accessible through a variety of approaches that would allow a potential to be delivered locally rather than systemically. This significantly broadens the potential medications that can be developed and opens the possibility of local gene delivery as a therapeutic intervention. Several potential clinical targets have been identified including delivery of neurotrophin expressing genes as an adjunct to cochlear implantation, delivery of protective genes to prevent trauma and the development of strategies for regenerating inner ear sensory cells. In order to translate these potential therapeutics into humans we will want to optimize the gene delivery methodology, dosing and activity of the drug for therapeutic value. To this end we have developed a series of adenovectors that efficiently transduce the inner ear. The use of these gene delivery approaches are attractive for the potential of hair cell regeneration after loss induced by trauma or ototoxins. This approach is particularly suited for the development of molecular therapies targeted at the vestibular system given that no device based therapeutic such a cochlear implant available for vestibular loss.
Dept. Otolaryngology Head and Neck Surgery, University of Kansas School of Medicine, MS 3010, 3901 Rainbow Blvd, Kansas City, KS 66209, USA. hstaecker@kumc.edu
Hinrich
H
Staecker
Mark
M
Praetorius
Douglas E
DE
Brough
D000256:Adenoviridae / Q000235:genetics / Q000276:immunology; D000818:Animals; D051792:Basic Helix-Loop-Helix Proteins / Q000235:genetics; D007758:Ear, Inner / Q000166:cytology; D018390:Gene Targeting; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000276:immunology; D006198:Hair Cells, Auditory / Q000502:physiology; D006801:Humans; D007759:Labyrinth Diseases / Q000628:therapy*; D023421:Models, Animal; D012038:Regeneration; D057170:Translational Research, Biomedical; D015837:Vestibular Diseases / Q000628:therapy
D051792:Basic Helix-Loop-Helix Proteins
Noise Health. 2001;3(11):37-47
12689447
Otolaryngol Clin North Am. 2004 Oct;37(5):1091-108
15474113
Int J Dev Biol. 2007;51(6-7):633-47
17891722
J Neurosci. 2010 Apr 28;30(17):5927-36
20427652
Hear Res. 2009 Feb;248(1-2):31-8
19105978
Science. 1993 Mar 12;259(5101):1619-22
8456285
ORL J Otorhinolaryngol Relat Spec. 2003 Jul-Aug;65(4):211-4
14564095
Brain Res Mol Brain Res. 2005 Jan 5;133(1):19-36
15661362
Nat Med. 2005 Mar;11(3):271-6
15711559
Nat Neurosci. 2000 Jun;3(6):580-6
10816314
Hear Res. 2007 Oct;232(1-2):44-51
17658230
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4084-8
10097167
J Am Acad Audiol. 2010 Mar;21(3):197-203
20211124
Gene Ther. 2009 Aug;16(8):990-7
19458651
J Neurosci. 2003 Jun 1;23(11):4395-400
12805278
Dev Biol. 2010 Jan 1;337(1):134-46
19854167
Adv Otorhinolaryngol. 2009;66:37-51
19494571
Dev Dyn. 2006 Jun;235(6):1689-700
16534784
Proc Natl Acad Sci U S A. 2001 May 8;98(10):5886-91
11331776
Curr Mol Med. 2001 May;1(2):245-58
11899074
Science. 1999 Jun 11;284(5421):1837-41
10364557
Otol Neurotol. 2007 Feb;28(2):223-31
17255891
Hear Res. 2009 Jan;247(1):17-26
18809482
J Gene Med. 1999 May-Jun;1(3):166-75
10738565
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):299-305
16384977
Brain Res. 2009 Jun 18;1276:31-8
19397899
Cell Cycle. 2008 Jul 15;7(14):2129-33
18635955
Hear Res. 2010 Jul;266(1-2):18-25
20438823
Int J Dev Neurosci. 1997 Jul;15(4-5):447-61
9263025
J Mol Med (Berl). 2006 Jan;84(1):37-45
16283144
Exp Hematol. 2006 Sep;34(9):1171-82
16939810
Mol Cell Neurosci. 2003 Jun;23(2):169-79
12812751
Hear Res. 2008 Jun;240(1-2):52-6
18430530
Audiol Neurootol. 2003 Mar-Apr;8(2):70-9
12634455
Audiol Neurootol. 1999 Nov-Dec;4(6):271-85
10516388
Hear Res. 2011 Mar;273(1-2):72-9
20488231
J Assoc Res Otolaryngol. 2009 Sep;10(3):321-40
19373512
Hear Res. 1995 Sep;89(1-2):194-202
8600126
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):781-5
18178626
Mol Ther. 2005 Jun;11(6):843-8
15922954
Hear Res. 2010 Aug;267(1-2):61-70
20433915
Gene Ther. 1996 Jul;3(7):588-92
8818645
J Assoc Res Otolaryngol. 2008 Mar;9(1):44-64
18057986
Mol Ther. 2001 Dec;4(6):575-85
11735342
Hear Res. 2002 Aug;170(1-2):22-31
12208538
Audiol Neurootol. 2010;15(6):353-63
20215744
DNA Cell Biol. 2002 Dec;21(12):895-913
12573049
J Neurocytol. 1999 Oct-Nov;28(10-11):809-19
10900086
Nature. 2008 Sep 25;455(7212):537-41
18754012
Neuroreport. 2007 Dec 3;18(18):1911-4
18007185
Int J Dev Neurosci. 1997 Jul;15(4-5):433-46
9263024
J Comp Neurol. 2006 Jul 20;497(3):502-18
16736472
J Assoc Res Otolaryngol. 2008 Mar;9(1):65-89
18157569
Acta Otolaryngol. 2010 Feb;130(2):215-22
20095092
Cell Mol Biol (Noisy-le-grand). 2005 Sep 02;51(1):3-22
16171561
Nat Neurosci. 2004 Dec;7(12):1310-8
15543141
Hear Res. 2002 Nov;173(1-2):187-97
12372646
J Assoc Res Otolaryngol. 2000 Sep;1(2):161-71
11545143
J Neurosci. 2001 Jul 1;21(13):4712-20
11425898
Curr Opin Otolaryngol Head Neck Surg. 2009 Oct;17(5):381-7
19623076
Laryngoscope. 1994 Jun;104(6 Pt 1):701-18
8196445